Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Johnson & Johnson To Acquire Early-Stage Eczema Treatment Developer Proteologix For $850M
Thursday, Johnson & Johnson (NYSE:JNJ) agreed to acquire Proteologix Inc., a privately held biotechnology company focused on bispecific antibodies for immune-mediated diseases, for $850 million in cash, with the potential for an additional milestone payment.
週四，強生公司（紐約證券交易所代碼：JNJ）同意以8.5億美元現金收購專注於免疫介導疾病雙特異性抗體的私營生物技術公司Proteologix Inc.，並有可能獲得額外的里程碑式付款。
Proteologix's portfolio includes:
Proteologix 的產品組合包括：
- PX128, a bispecific antibody targeting IL-13 plus TSLP, which is ready to enter phase 1 development for moderate to severe atopic dermatitis (AD) and moderate to severe asthma.
- PX130, a bispecific antibody targeting IL-13 plus IL-22, which is in preclinical development for moderate to severe AD.
- PX128 是一種靶向 IL-13 和 TSLP 的雙特異性抗體，已準備好進入針對中度至重度特應性皮炎 (AD) 和中度至重度哮喘的 1 期開發。
- PX130，一種靶向 IL-13 和 IL-22 的雙特異性抗體，目前正在針對中度至重度 AD 進行臨床前開發。
PX128 inhibits IL-13-mediated Th2 skin inflammation, an important disease-driving pathway in AD and asthma, and TSLP, a mediator of tissue inflammation in AD and asthma.
PX128 抑制 IL-13 介導的 Th2 皮膚炎症，這是 AD 和哮喘的重要疾病驅動途徑，TSLP 是 AD 和哮喘組織炎症的介質。
Like PX128, PX130 inhibits IL-13-mediated Th2 skin inflammation.
與 PX128 一樣，PX130 抑制 IL-13 介導的 Th2 皮膚炎症。
PX130 also inhibits IL-22 to restore the skin barrier and prevent inflammation from environmental triggers, such as allergens.
PX130 還抑制 IL-22 以恢復皮膚屏障，防止過敏原等環境誘因引起的炎症。
Both assets are designed for infrequent dosing intervals.
兩種資產都是爲不頻繁的給藥間隔而設計的。
"We see an opportunity for best-in-disease efficacy for both PX128 and PX130 as each bispecific antibody targets two different combinations of disease-driving pathways that are mediating the skin inflammation in heterogenous subpopulations of AD patients," said David Lee, Global Immunology Therapeutic Area Head, Johnson & Johnson Innovative Medicine
強生創新醫學全球免疫學治療領域負責人戴維·李說：“我們看到 PX128 和 PX130 都有機會實現病中最佳療效，因爲每種雙特異性抗體都針對介導 AD 患者異源亞群皮膚炎症的兩種不同的疾病驅動途徑組合。”
In addition to PX128 and PX130, the acquisition will provide J&J with other bispecific antibody programs with applications across various other diseases, further boosting the company's capabilities to create novel bispecific programs.
除了 PX128 和 PX130 外，此次收購還將爲強生提供其他雙特異性抗體項目，可應用於其他各種疾病，進一步提高該公司創建新型雙特異性計劃的能力。
Atopic dermatitis (AD), also known as eczema, is a chronic inflammatory skin disorder that affects more than 102.8 million children and 101.3 million adults worldwide.
特應性皮炎（AD），也稱爲溼疹，是一種慢性炎症性皮膚病，影響全球超過1.028億兒童和1.013億成人。
Recently, Johnson & Johnson agreed to acquire Shockwave Medical Inc. (NASDAQ:SWAV) for $335 per share in cash, corresponding to an enterprise value of approximately $13.1 billion, including the cash acquired.
最近，強生公司同意以每股現金335美元收購Shockwave Medical Inc.（納斯達克股票代碼：SWAV），相當於包括收購現金在內的企業價值約131億美元。
Price Action: JNJ shares are up 0.53% at $153.48 at last check Thursday.
價格走勢：在週四的最後一次檢查中，JNJ股價上漲0.53％，至153.48美元。
Photo via Shutterstock
照片來自 Shutterstock
譯文內容由第三人軟體翻譯。